cellvie secures $5 million to accelerate clinical translation

cellvie, a pioneer in mitochondrial-based therapeutics, has secured fresh funding from both existing and new investors. The round was led by Taiho Ventures, with major contributions also coming from another existing investor, Kizoo Technology Capital, and Beiersdorf Venture Capital. With the additional capital, cellvie will accelerate the clinical translation of its lead program in kidney transplantation, and to further hone its pipeline.
Read the full article at Startupticker